The Phase 2 trial of retatrutide (Jastreboff et al., New England Journal of Medicine , 2023) reported that the most common adverse effects were gastrointestinal in nature (nausea, vomiting, diarrhoea), consistent with the GLP-1 receptor agonist class
People who have lived here their whole lives are only used to what they see here, which is warehouse. What's next
Results vary by individual and goal
Some individuals may experience: Mild injection site irritation or warmth Temporary flushing or tingling Nausea or lightheadedness Rare headache or fatigue Most side effects are mild and transient
Protein is more in demand than ever because people are focusing on strength, muscle health and long-term health especially amid weight-loss journeys or GLP-1 treatment
Presented for research literature review only Lian LY (1998)